Evidence map›Paper›PMID 26053404›Full record

ArticlePloS one2015

Comprehensive Analysis of Disease-Related Genes in Chronic Lymphocytic Leukemia by Multiplex PCR-Based Next Generation Sequencing.

Claudia Vollbrecht, Fabian Dominik Mairinger, Ulrike Koitzsch, Martin Peifer, Katharina Koenig, Lukas Carl Heukamp, Giuliano Crispatzu, Laura Wilden, Karl-Anton Kreuzer, Michael Hallek and 3 more

Open access · goldAbstract read
In one paragraph

Article in PloS one, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.

0numbers the graph read from it
0cells of the map it votes in
16citing papers in PubMed
2.1field-weighted citation impact, top 14% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

16 citing papers in PubMed, 27 citations in OpenAlex.

  1. Review
  2. Altered DNA Methylation Profiles inInternational journal of molecular sciences · 2021
    Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Review
  10. Review
  11. Article
  12. Article
  13. Detection approaches for multidrug resistance genes of leukemia.Drug design, development and therapy · 2017
    Review
  14. Article
  15. Article
  16. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 4 institutions in 1 country.

Claudia VollbrechtInstitute of Pathology, University Hospital Cologne, Cologne, Germany; Center for Integrated Oncology (CIO) Cologne-Bonn, University Hospital Cologne, Cologne, Germany; Center of Molecular Medicine Cologne, University of Cologne, Cologne, Germany.
Fabian Dominik MairingerInstitute of Pathology, University Hospital Essen, University of Duisburg-Essen, Essen, Germany.
Ulrike KoitzschInstitute of Pathology, University Hospital Cologne, Cologne, Germany; Center for Integrated Oncology (CIO) Cologne-Bonn, University Hospital Cologne, Cologne, Germany; Center of Molecular Medicine Cologne, University of Cologne, Cologne, Germany.
Martin PeiferCenter of Molecular Medicine Cologne, University of Cologne, Cologne, Germany; Department of Translational Genomics, Cologne Center of Genomics, University of Cologne, Cologne, Germany.
Katharina KoenigInstitute of Pathology, University Hospital Cologne, Cologne, Germany; Center for Integrated Oncology (CIO) Cologne-Bonn, University Hospital Cologne, Cologne, Germany; Center of Molecular Medicine Cologne, University of Cologne, Cologne, Germany.
Lukas Carl HeukampInstitute of Pathology, University Hospital Cologne, Cologne, Germany; Center for Integrated Oncology (CIO) Cologne-Bonn, University Hospital Cologne, Cologne, Germany.
Giuliano CrispatzuCenter for Integrated Oncology (CIO) Cologne-Bonn, University Hospital Cologne, Cologne, Germany; Department I of Internal Medicine, University Hospital Cologne, Cologne, Germany; Excellence Cluster for Cellular Stress Response and Aging-Associated Diseases (CECAD), University of Cologne, Cologne, Germany.
Laura WildenCenter for Integrated Oncology (CIO) Cologne-Bonn, University Hospital Cologne, Cologne, Germany; Department I of Internal Medicine, University Hospital Cologne, Cologne, Germany.
Karl-Anton KreuzerCenter for Integrated Oncology (CIO) Cologne-Bonn, University Hospital Cologne, Cologne, Germany; Department I of Internal Medicine, University Hospital Cologne, Cologne, Germany.
Michael HallekCenter for Integrated Oncology (CIO) Cologne-Bonn, University Hospital Cologne, Cologne, Germany; Department I of Internal Medicine, University Hospital Cologne, Cologne, Germany.
Margarete OdenthalInstitute of Pathology, University Hospital Cologne, Cologne, Germany; Center for Integrated Oncology (CIO) Cologne-Bonn, University Hospital Cologne, Cologne, Germany; Center of Molecular Medicine Cologne, University of Cologne, Cologne, Germany.
Carmen Diana HerlingCenter for Integrated Oncology (CIO) Cologne-Bonn, University Hospital Cologne, Cologne, Germany; Department I of Internal Medicine, University Hospital Cologne, Cologne, Germany.
Reinhard BuettnerInstitute of Pathology, University Hospital Cologne, Cologne, Germany; Center for Integrated Oncology (CIO) Cologne-Bonn, University Hospital Cologne, Cologne, Germany; Center of Molecular Medicine Cologne, University of Cologne, Cologne, Germany.
University Hospital Cologne · DECologne Excellence Cluster on Cellular Stress Responses in Aging Associated Diseases · DEUniversity of Cologne · DEUniversity of Duisburg-Essen · DE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundHigh resolution molecular studies have demonstrated that the clonal acquisition of gene mutations is an important mechanism that may promote rapid disease progression and drug resistance in chronic lymphocytic leukemia (CLL). Therefore, the early and sensitive detection of such mutations is an important prerequisite for future predictive CLL diagnostics in the clinical setting. MATERIAL &

methodsHere, we describe a novel, target-specific next generation sequencing (NGS) approach, which combines multiplex PCR-based target enrichment and library generation with ultra-deep high-throughput parallel sequencing using a MiSeq platform. We designed a CLL specific target panel, covering hotspots or complete coding regions of 15 genes known to be recurrently mutated and/or related to B-cell receptor signaling.

resultsHigh-throughput sequencing was performed using as little as 40 ng of peripheral blood B-cell DNA from 136 CLL patients and a dilution series of two ATM- or TP53-mutated cell lines, the latter of which demonstrated a limit of mutation detection below 5%. Using a stringent functional assessment algorithm, 102 mutations in 8 genes were identified in CLL patients, including hotspot regions of TP53, SF3B1, NOTCH1, ATM, XPO1, MYD88, DDX3X and the B-cell receptor signaling regulator PTPN6. The presence of mutations was significantly associated with an advanced disease status und molecular markers of an inferior prognosis, such as an unmutated IGHV mutation status or positivity for ZAP70 by flow cytometry.

conclusionIn summary, targeted sequencing using an amplicon based library technology allows a resource-efficient and sensitive mutation analysis for diagnostic or exploratory purposes and facilitates molecular subtyping of patient sets with adverse prognosis.

Indexed as

Genetic Association StudiesHigh-Throughput Nucleotide SequencingMultiplex Polymerase Chain ReactionAdultAgedAged, 80 and overFemaleGene LibraryGenetic VariationHumansLeukemia, Lymphocytic, Chronic, B-CellMaleMiddle AgedMutationPrognosisSensitivity and Specificity

Identifiers

PMID26053404
PMCPMC4459702
OpenAlexW562743080

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.